Central Coast coalition aims to launch aerospace economy from Ventura to Santa Cruz
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Teledyne shares hit record after strong earnings report
The acquisition of Flir Systems continues to pay off for Teledyne Technologies, as the Thousand Oaks-based industrial and scientific conglomerate crushed analysts’ expectations in the third quarter and upped its guidance for the full year. Teledyne delivered record sales for the quarter ended Sept. 30, generating $1.3 billion in revenue, a 75.8% increase from the Read More →
Region’s unemployment rate drops below 5%
The unemployment rate in the tri-county region dropped nearly a full percentage point between August and September, to reach its lowest level since before the COVID-19 pandemic began. The combined unemployment rate of Ventura, Santa Barbara and San Luis Obispo counties was just under 5% in September, down from 5.9% in August, according to a Read More →
Energy Vault preps to go public, could raise $388M
Westlake Village-based Energy Vault disclosed details of its financial performance for the first time in an Oct. 18 filing with the U.S. Securities and Exchange Commission, filed in advance of its public stock offering and its pending merger with a special purpose acquisition company. Energy Vault, a green energy storage company, agreed to go public Read More →
MannKind shares drop 18% after FDA says it will pass on new blood pressure drug
Shares of Westlake Village-based MannKind Corp. dropped 18% on Oct. 18, after the U.S. Food and Drug Administration did not approve a hypertension treatment the company is developing with United Therapeutics. In a complete letter response, the FDA declined to approve a new drug application for Tyvasio DPI, a treatment being developed by MannKind and Read More →
Amgen’s investment in Neumora marks a return to neuroscience research
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen goes full speed ahead on biosimilar drugs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
